Cancer Progress Requires Integrating Data And Therapeutics – AACR Report
As genomic analysis produces ever-increasing amounts of data on cancer biology, continued progress in oncology will require advances in managing and analyzing data and new approaches to clinical trial design to increase efficiency and address development of treatment resistance to molecularly targeted therapies, the American Association for Cancer Research asserts in its annual Cancer Progress report.
You may also be interested in...
Rapid advances in genetic screening technology have prompted an FDA effort to overhaul its approach to diagnostic regulation and to consider ways to make genomic data available to the health system.
Sponsors stress that basket trials are designed to find signals of activity that will be followed up with randomized, controlled studies, but NEJM editorial wonders if off-label prescribing will circumvent those intentions.
With current technology and resources, a well-funded in vitro diagnostics company can create and pursue a strategy of information gathering and informatics application to create medical knowledge, enabling it to assume the risk and manage certain segments of patients. But few if any pharma or diagnostics firms appear poised to take advantage.